Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
•
Internal Medicine
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
If so, what is the recommended starting dose you would use?
Related Questions
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?